How to know the dosage and usage of cabergoline

Cabergoline is a dopamine receptor agonist. It is mainly used clinically to treat hyperprolactinemia (HPRL) and the symptoms such as amenorrhea, infertility, galactorrhea and other symptoms caused by it. Reasonable control of usage and dosage is crucial to ensure efficacy and reduce the risk of adverse reactions. According to international mainstream guidelines, the recommended starting dose of cabergoline is usually 0.25 mg each time, taken twice a week, and it is recommended to take it orally after meals to reduce gastrointestinal discomfort.

Due to large individual differences, the serum prolactin level must be used as a reference during the treatment process to adjust the dose step by step. It is generally recommended that the dosage increase should not exceed 0.25mg each time, and the adjustment interval should be at least four weeks to ensure that the body has enough time to adapt to the effects of the drug. Clinical observation shows that some patients can obtain satisfactory efficacy at lower doses. However, for those who have insufficient response to the drug, the dose can be gradually increased to the maximum recommended dose, which is 1 mg each time, twice a week. There is still a lack of sufficient data on the safety of exceeding this dose, so it is not appropriate to increase it arbitrarily.

It is important to note that clinicians may consider discontinuing the drug when the patient's serum prolactin levels return to normal and are maintained for at least six months. However, hormone levels still need to be monitored regularly after discontinuation of medication, and treatment should be resumed promptly if signs of recurrence appear. In practice, it has been found that some patients can still maintain long-term remission after stopping the drug, but some patients will experience a rebound in levels, indicating that the treatment strategy of cabergoline needs to be dynamically adjusted.

For patients with cardiovascular disease or abnormal liver function, the starting dose and adjustment plan need to be extremely cautious, and it is best to implement it under the guidance of a specialist. In addition, cabergoline has a long half-life and can generally be taken twice a week. Patients do not need to take medication every day, which is conducive to long-term compliance. This is also one of its important advantages compared with other dopamine agonists.

Reference materials:https://www.drugs.com/mtm/cabergoline.html